Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$172.67+10.49 (+6.47%)
Close on Nov 18, 2026Market cap $11.04BP/E –Yield –
Repligen revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Repligen's revenue for the twelve months ending Sep 30, 2026 was $805.61M, up 13.8% year over year. For fiscal 2025 it was $738.26M, up 16.4% from the year before. Over ten years it grew 24.3% a year on average. The highest annual figure on record is $801.54M in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $738.26M | +16.4% |
| FY2024 | Dec 31, 2024 | $634.44M | +0.3% |
| FY2023 | Dec 31, 2023 | $632.36M | -21.1% |
| FY2022 | Dec 31, 2022 | $801.54M | +19.5% |
| FY2021 | Dec 31, 2021 | $670.53M | +83.1% |
| FY2020 | Dec 31, 2020 | $366.26M | +35.5% |
| FY2019 | Dec 31, 2019 | $270.25M | +39.3% |
| FY2018 | Dec 31, 2018 | $194.03M | +37.4% |
| FY2017 | Dec 31, 2017 | $141.24M | +35.1% |
| FY2016 | Dec 31, 2016 | $104.54M | +25.1% |
| FY2015 | Dec 31, 2015 | $83.54M | +31.5% |
| FY2014 | Dec 31, 2014 | $63.55M | -6.8% |
| FY2013 | Dec 31, 2013 | $68.17M | +149.8% |
| FY2011 | Mar 31, 2011 | $27.29M | +30.1% |
| FY2010 | Mar 31, 2010 | $20.97M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $209.31M | +10.9% |
| Q2 FY2026 | Jun 30, 2026 | $204.13M | +11.9% |
| Q1 FY2026 | Mar 31, 2026 | $194.26M | +14.8% |
| Q4 FY2025 | Dec 31, 2025 | $197.91M | +18.1% |
| Q3 FY2025 | Sep 30, 2025 | $188.81M | +21.9% |
| Q2 FY2025 | Jun 30, 2025 | $182.37M | +14.8% |
| Q1 FY2025 | Mar 31, 2025 | $169.17M | +10.4% |
| Q4 FY2024 | Dec 31, 2024 | $167.55M | +0.6% |
| Q3 FY2024 | Sep 30, 2024 | $154.87M | +9.7% |
| Q2 FY2024 | Jun 30, 2024 | $158.84M | -0.2% |
| Q1 FY2024 | Mar 31, 2024 | $153.18M | -7.4% |
| Q4 FY2023 | Dec 31, 2023 | $166.62M | -10.8% |
| Q3 FY2023 | Sep 30, 2023 | $141.19M | -29.7% |
| Q2 FY2023 | Jun 30, 2023 | $159.17M | -23.3% |
| Q1 FY2023 | Mar 31, 2023 | $165.38M | -19.9% |
| Q4 FY2022 | Dec 31, 2022 | $186.76M | +0.1% |
| Q3 FY2022 | Sep 30, 2022 | $200.74M | +12.6% |
| Q2 FY2022 | Jun 30, 2022 | $207.63M | +27.4% |
| Q1 FY2022 | Mar 31, 2022 | $206.40M | +44.5% |
| Q4 FY2021 | Dec 31, 2021 | $186.52M | +71.7% |
| Q3 FY2021 | Sep 30, 2021 | $178.22M | +89.5% |
| Q2 FY2021 | Jun 30, 2021 | $162.96M | +86.3% |
| Q1 FY2021 | Mar 31, 2021 | $142.84M | +87.7% |
| Q4 FY2020 | Dec 31, 2020 | $108.65M | +56.4% |
| Q3 FY2020 | Sep 30, 2020 | $94.06M | +35.4% |
| Q2 FY2020 | Jun 30, 2020 | $87.46M | +23.7% |
| Q1 FY2020 | Mar 31, 2020 | $76.09M | +25.5% |
| Q4 FY2019 | Dec 31, 2019 | $69.47M | +33.8% |
| Q3 FY2019 | Sep 30, 2019 | $69.45M | +40.2% |
| Q2 FY2019 | Jun 30, 2019 | $70.69M | +48.1% |
| Q1 FY2019 | Mar 31, 2019 | $60.63M | +35.3% |
| Q4 FY2018 | Dec 31, 2018 | $51.94M | +24.8% |
| Q3 FY2018 | Sep 30, 2018 | $49.53M | +35.4% |
| Q2 FY2018 | Jun 30, 2018 | $47.73M | +47.1% |
| Q1 FY2018 | Mar 31, 2018 | $44.83M | +46.6% |
| Q4 FY2017 | Dec 31, 2017 | $41.61M | +62.5% |
| Q3 FY2017 | Sep 30, 2017 | $36.58M | – |
| Q2 FY2017 | Jun 30, 2017 | $32.46M | – |
| Q1 FY2017 | Mar 31, 2017 | $30.59M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.60M | – |
See a number that looks wrong?